Petros PharmaceuticalsPTPI Quick Ratio is 1.68 as of Mar. 2026, which is 15% above its 10-year median of 1.46. Among 997 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 57.17% on this metric.
Petros Pharmaceuticals has a quick ratio of 1.68. It generally indicates good short-term financial strength.
The historical rank and industry rank for Petros Pharmaceuticals's Quick Ratio or its related term are showing as below:
PTPI'
s Quick Ratio Range Over the Past 10 Years
Min: 0.24 Med: 1.46 Max: 2.84
Current: 1.68
During the past 7 years, Petros Pharmaceuticals's highest Quick Ratio was 2.84. The lowest was 0.24. And the median was 1.46.
PTPI's Quick Ratio is ranked better than 57.17% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs PTPI: 1.68
Petros Pharmaceuticals (OTCPK:PTPI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Petros Pharmaceuticals Quick Ratio Related Terms
Petros Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Petros Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a Quick Ratio of 1.68 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Petros Pharmaceuticals and its competitors. This is 15% above median its historical median of 1.46. Over the past decade, Petros Pharmaceuticals' Quick Ratio has ranged from 0.24 to 2.84. According to the industry distribution chart, Petros Pharmaceuticals ranks #427 out of 997 companies in the Drug Manufacturers industry, placing it in the top 42.8%.
Is Petros Pharmaceuticals' Quick Ratio too high?
Petros Pharmaceuticals' current Quick Ratio of 1.68 is 15% above median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 2.84. The Drug Manufacturers industry median Quick Ratio is 1.45. Petros Pharmaceuticals' value of 1.68 is 15.9% above this industry median. Based on the distribution chart, Petros Pharmaceuticals ranks #427 out of 997 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Petros Pharmaceuticals' Quick Ratio compare to GCAN and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #427 out of 997 companies for Quick Ratio. This puts Petros Pharmaceuticals in the upper half of its industry. The industry median Quick Ratio is 1.45. Petros Pharmaceuticals' value of 1.68 is 15.9% above this benchmark. Historically, Petros Pharmaceuticals' own Quick Ratio has ranged from 0.24 to 2.84 over the past decade. While the company's 10-year median is 1.46 vs. the industry median of 1.45, Petros Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petros Pharmaceuticals's current Quick Ratio of 1.68 is 15.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current Quick Ratio is 1.68, which is 15% above median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Quick Ratio of 1.68. The current Quick Ratio is 1.68, which is 15% above median its 10-year median of 1.46 and 15.9% above the Drug Manufacturers industry median of 1.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Quick Ratio is 1.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 